Home Acta Virologica 2018 Acta Virologica Vol.62, No.3, p.259-265, 2018

Journal info


Quarterly,
Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Aims and Scope
Abstracted and Indexed

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.62, No.3, p.259-265, 2018

Title: Drug resistance-associated mutations in antiretroviral treatment-naïve and -experienced patients in Kuwait
Author: W. CHEHADEH, O. ALBAKSAMI, S. E. JOHN, W. AL-NAKIB

Abstract: The identification of human immunodeficiency virus (HIV) mutations leading to drug resistance enables patient-specific adaptation of the treatment regimen and predicts the risk of transmission of drug-resistant HIV. In this study, we report for the first time the prevalence in Kuwait of non-polymorphic resistance-associated mutations (RAMs) in patients under first-line antiretroviral therapy. Viral RNA was extracted from plasma samples of 64 treatment-naïve (untreated) and 64 treatment-experienced patients. The HIV-1 load was determined by real-time RT-PCR. The protease- and reverse transcriptase-encoding regions were analyzed by subtyping, and for drug resistance. The HIV-1 load at sampling in treatment-naïve patients ranged from 1.61 x 104 to 1.91 x 106 copies/ml, whereas that in treatment-experienced patients ranged from bitors (PIs) and NNRTIs. These results necessitate efforts to be made for reducing emergence of resistance-associated mutations in treated patients, and highlight the need for continuous monitoring of drug resistance patterns in Kuwait.

Keywords: HIV-1; genotyping; mutations; drug resistance; surveillance; Kuwait
Published online: 30-Aug-2018
Year: 2018, Volume: 62, Issue: 3 Page From: 259, Page To: 265
doi:10.4149/av_2018_219


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.